文献速递肝病

非酒精性脂肪性肝病遗传学更新:从新变异到临床

Update on NAFLD genetics: From new variants to the clinic.
PubMed 文献 · J Hepatol · 2020-03-04

非酒精性脂肪性肝病(NAFLD)在高收入国家是主要肝病负担,个体风险受环境与遗传因素影响。全基因组关联研究已发现PNPLA3、TM6SF2、MBOAT7、GCKR、HSD17B13等基因变异与NAFLD自然史稳健相关,多基因风险评分在NAFLD风险分层中的临床验证受到关注。本文综述NAFLD遗传架构、基因-环境交互及对疾病病理生物学、药物发现和风险预测的意义,并讨论临床转化前的方法学障碍。

要点

  • PNPLA3、TM6SF2、MBOAT7、GCKR、HSD17B13等基因变异与NAFLD自然史稳健相关。
  • 多基因风险评分在NAFLD风险分层中的临床验证是当前研究热点。
  • 遗传发现向日常实践转化前仍需克服方法学障碍。

核心结论

  • NAFLD遗传变异(如PNPLA3、TM6SF2等)为疾病生物学和药物靶点提供新见解,但临床转化仍需方法学验证。

研究设计与样本

  • 综述类文章,总结NAFLD遗传架构、基因-环境交互及临床转化 implications。

主要发现

  • 全基因组关联研究揭示PNPLA3、TM6SF2、MBOAT7、GCKR、HSD17B13等基因变异与NAFLD自然史稳健且可重复关联。
  • 多基因风险评分在心血管疾病和乳腺癌等复杂性状的临床风险预测中显示前景,为NAFLD遗传变异临床验证提供新动力。

临床怎么用

  • 遗传变异可用于NAFLD风险分层的潜在临床验证,但需先解决方法学障碍才能日常实践。

局限性

  • 遗传发现临床转化前需克服方法学障碍,具体障碍未在摘要中详述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver diseases in high-income countries and the burden of NAFLD is increasing at an alarming rate. The risk of developing NAFLD and related complications is highly variable among individuals and is determined by environmental and genetic factors. Genome-wide association studies have uncovered robust and reproducible associations between variations in genes such as PNPLA3, TM6SF2, MBOAT7, GCKR, HSD17B13 and the natural history of NAFLD. These findings have provided compelling new insights into the biology of NAFLD and highlighted potentially attractive pharmaceutical targets. More recently the development of polygenic risk scores, which have shown promising results for the clinical risk prediction of other complex traits (such as cardiovascular disease and breast cancer), have provided new impetus for the clinical validation of genetic variants in NAFLD risk stratification. Herein, we review current knowledge on the genetic architecture of NAFLD, including gene-environment interactions, and discuss the implications for disease pathobiology, drug discovery and risk prediction. We particularly focus on the potential clinical translation of recent genetic advances, discussing methodological hurdles that must be overcome before these discoveries can be implemented in everyday practice.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Trépo E, Valenti L. Update on NAFLD genetics: From new variants to the clinic. J Hepatol. 2020. PMID: 32145256. doi:10.1016/j.jhep.2020.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。